<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
<record>
  <controlfield tag="001">165656</controlfield>
  <controlfield tag="005">20260114125841.0</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="2">doi</subfield>
    <subfield code="a">10.1515/dmpt-2018-0017</subfield>
  </datafield>
  <datafield tag="024" ind1="8" ind2=" ">
    <subfield code="2">sideral</subfield>
    <subfield code="a">109091</subfield>
  </datafield>
  <datafield tag="037" ind1=" " ind2=" ">
    <subfield code="a">ART-2018-109091</subfield>
  </datafield>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Rodríguez Vicente, A.E.</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Personalized medicine into health national services: Barriers and potentialities</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2018</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Access copy available to the general public</subfield>
    <subfield code="f">Unrestricted</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Research and innovation in personalized medicine (PM) are extensive and expanding, with several pharmacogenetic/pharmacogenomic (PGx) testing options currently available for a wide range of health problems. However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by practitioner/patient: utilization and uptake by payers in real-world practice are being discussed, and the criteria to guide clinicians and policy makers in PGx test selection are not fully incorporated. This review focuses on the advances of pharmacogenomics to individualize treatments, the relationship between pharmacogenetics and pharmacometabolomics, the new paradigm of the Big Data, the needs and barriers facing PGx clinical application and the situation of PGx testing in health national services. It is based on lectures presented by speakers of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) Fourth Conference, held in Catania, October 4th, 2017.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="9">info:eu-repo/semantics/openAccess</subfield>
    <subfield code="a">by-nc</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by-nc/4.0/deed.es</subfield>
  </datafield>
  <datafield tag="592" ind1=" " ind2=" ">
    <subfield code="a">0.277</subfield>
    <subfield code="b">2018</subfield>
  </datafield>
  <datafield tag="593" ind1=" " ind2=" ">
    <subfield code="a">Pharmacology, Toxicology and Pharmaceutics (miscellaneous)</subfield>
    <subfield code="c">2018</subfield>
    <subfield code="d">Q2</subfield>
  </datafield>
  <datafield tag="593" ind1=" " ind2=" ">
    <subfield code="a">Pharmacology (medical)</subfield>
    <subfield code="c">2018</subfield>
    <subfield code="d">Q2</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">info:eu-repo/semantics/article</subfield>
    <subfield code="v">info:eu-repo/semantics/acceptedVersion</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Herrero Cervera, M.J.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Bernal, M.L.</subfield>
    <subfield code="u">Universidad de Zaragoza</subfield>
    <subfield code="0">(orcid)0000-0002-8222-1418</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Rojas, L.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Peiró, A.M.</subfield>
  </datafield>
  <datafield tag="710" ind1="2" ind2=" ">
    <subfield code="1">1005</subfield>
    <subfield code="2">315</subfield>
    <subfield code="a">Universidad de Zaragoza</subfield>
    <subfield code="b">Dpto. Farmacología y Fisiolog.</subfield>
    <subfield code="c">Área Farmacología</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="g">33, 4 (2018), 159-163</subfield>
    <subfield code="p">Drug metab. person. ther.</subfield>
    <subfield code="t">Drug metabolism and personalized therapy</subfield>
    <subfield code="x">2363-8907</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">162395</subfield>
    <subfield code="u">http://zaguan.unizar.es/record/165656/files/texto_completo.pdf</subfield>
    <subfield code="y">Postprint</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">2761160</subfield>
    <subfield code="u">http://zaguan.unizar.es/record/165656/files/texto_completo.jpg?subformat=icon</subfield>
    <subfield code="x">icon</subfield>
    <subfield code="y">Postprint</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zaguan.unizar.es:165656</subfield>
    <subfield code="p">articulos</subfield>
    <subfield code="p">driver</subfield>
  </datafield>
  <datafield tag="951" ind1=" " ind2=" ">
    <subfield code="a">2026-01-14-12:57:59</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">ARTICLE</subfield>
  </datafield>
</record>
</collection>